This article reviews the use of combination emtricitabine (FTC)/tenofovir as preexposure prophylaxis (PrEP) for HIV-negative patients at high risk of acquiring HIV, including heterosexual men and women, men who have sex with men, and IV drug users. When used with classic prevention strategies such as condoms, PrEP has been found effective in reducing the risk of HIV transmission.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.JAA.0000456567.37724.e0 | DOI Listing |
Publication Analysis
Top Keywords
preexposure prophylaxis
8
oral preexposure
4
prophylaxis prevent
4
prevent hiv
4
hiv infection
4
infection clinical
4
clinical public
4
public health
4
health implications
4
implications article
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!